文献速递泌尿生殖MR

前列腺动态对比增强MR成像:钆特酸葡甲胺与钆布醇的个体内比较

Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.
PubMed 文献 · Eur Radiol · 2019-07-01

该回顾性、非对照、非随机研究纳入50例患者,在3T MR上个体内比较0.5 M钆特酸葡甲胺与1.0 M钆布醇在等摩尔剂量(0.1 mmol/kg)和相同注射速度(2 mL/s)下前列腺DCE-MR的强化效果。钆布醇组BPH结节的时间-强化曲线下面积(5.53 vs 4.97,p=0.0007)和相对强化率(2.23 vs 1.96,p<0.0001)显著高于钆特酸葡甲胺组,但SNR、CNR及药代动力学参数无显著差异。

要点

  • 等摩尔剂量下钆布醇较钆特酸葡甲胺在前列腺BPH结节DCE-MR早期(180秒内)提供更高相对强化。
  • 两种对比剂在延迟期SNR、CNR及药代动力学参数Ktrans、Ve、Kep上无显著差异。
  • 钆布醇因浓度更高(1.0 M vs 0.5 M)在相同注射速度下钆输送率更高,可能影响强化曲线解读。

核心结论

  • 等摩尔剂量下,钆布醇较钆特酸葡甲胺在前列腺BPH结节DCE-MR中提供更高的相对强化参数,但未转化为SNR或CNR的改善。

研究设计与样本

  • IRB批准的回顾性、非对照、非随机个体内比较研究,纳入50例接受两次3-T MR前列腺检查的患者(平均间隔20.5个月),分别使用0.5 M钆特酸葡甲胺和1.0 M钆布醇,等摩尔剂量0.1 mmol/kg体重,相同注射速度2 mL/s;在两次扫描的BPH结节上确定相同感兴趣区(ROItz),计算0至180秒时间-强化曲线下面积及药代动力学参数,并比较延迟期(约180秒)相对强化、SNR和CNR。

诊断标准与关键数值

  • 钆布醇组较钆特酸葡甲胺组:时间-强化曲线下面积5.53 vs 4.97(p=0.0007),BPH结节相对强化2.23 vs 1.96(p<0.0001);SNR 44.55 vs 37.63(p=0.12)、CNR 31.22 vs 26.39(p=0.18)、Ktrans 0.31 vs 0.32(p=0.86)、Ve 1.36 vs 0.98(p=0.13)、Kep 0.34 vs 0.36(p=0.12)均无显著差异。

临床应用与阅片要点

  • 作者结论指出,等摩尔剂量下钆布醇因钆输送率更高可提供更高的相对强化参数,但未改善SNR或CNR;原文未据此给出进一步推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To intraindividually compare the signal-enhancing effect of 0.5 M gadoterate meglumine and 1.0 M gadobutrol in dynamic contrast-enhanced magnetic resonance (DCE-MR) imaging of the prostate.

METHODS: Fifty patients who underwent two 3-T MR examinations of the prostate were included in this IRB-approved retrospective uncontrolled, unrandomized study. All received two scans (mean time interval, 20.5 months) including T1-weighted DCE-MR imaging, one with 0.5 M gadoterate meglumine and one with 1.0 M gadobutrol. Equimolar doses of gadolinium (0.1 mmol/kg body weight) were administered with identical injection speed (2 mL/s), resulting in differing gadolinium delivery rate. An identical region of interest (ROItz) within a BPH-node was identified on both scans. The area under the time-enhancement curve of each ROItz from 0 to 180 s post contrast arrival and pharmacokinetic parameters were calculated. Relative enhancement and signal-to-noise (SNR) and contrast-to-noise (CNR) ratios in the delayed phase at about 180 s were compared between both agents.

RESULTS: There was a significantly larger area under the time-enhancement curve (5.53 vs 4.97 p = 0.0007) and higher relative enhancement of BPH nodules (2.23 vs 1.96 p < 0.0001) with gadobutrol compared with gadoterate meglumine. There were no significant differences in SNR (44.55 vs 37.63 p = 0.12), CNR (31.22 vs 26.39 p = 0.18), and pharmacokinetic parameters Ktrans (0.31 vs 0.32 p = 0.86), Ve (1.36 vs 0.98 p = 0.13), and Kep (0.34 vs 0.36 p = 0.12).

CONCLUSIONS: At equimolar doses, increased gadolinium delivery over time using gadobutrol provides higher relative enhancement parameters in BPH nodules compared with gadoterate meglumine, but does not translate into improved SNR or CNR.

KEY POINTS: • At equal injection rate and equimolar total dose, gadobutrol compared with gadoterate meglumine provides a significantly greater relative enhancement in DCE-MR imaging of BPH over the first 180 s. • There are no significant differences in SNRs, CNRs, and pharmacokinetic parameters between the two GBCAs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lee CH, Vellayappan B, Taupitz M, et al. Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol. Eur Radiol. 2019. PMID: 31264013. doi:10.1007/s00330-019-06321-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。